电邮这篇文章 The therapy for early relapsed chronic lymphocytic leukemia: the development of the problem The results of the project with the discussion concerning the possibility of optimization approaches for the therapy
- 期: 卷 23, 编号 4 (2021)
- 页面: 610-611
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/100144
- DOI: https://doi.org/10.26442/18151434.2021.4.201331
- ID: 100144
如何引用文章
全文:
详细
The Russian Oncohematology Society with the support of AbbVie completed the project that allows Russian hematologists to discuss the possibilities of optimization approaches for the therapy for early relapsed chronic lymphocytic leukemia, during 2021. The consolidated opinion of the specialists for several clinical situations was formulated at the final meeting.
参考
- Kater AP, Kipps TJ, Eichhorst B, et al. Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). ASH. 2020; Oral presentation 125.
- Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-7. doi: 10.1182/blood-2014-09-603670
- Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. doi: 10.1001/jamaoncol.2014.218
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-36. doi: 10.1056/NEJMoa1815281
- Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269-77. doi: 10.1200/JCO.18.01580
- Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042-54. doi: 10.1200/JCO.20.00948
补充文件
